← Eichor
Study identifier: NCT07620665 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Opiranserin for Minimally Invasive Cholecystectomy

Condition: Cholecystectomy, Laparoscopic · Cholecystectomy, Robotic  ·  Sponsor: Gangnam Severance Hospital

PhaseNA
Planned participants88
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate whether the combination therapy of opiranserin and acetaminophen is non-inferior to the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for postoperative pain management after minimally invasive cholecystectomy. This is a single-center, randomized, controlled, non-inferiority clinical trial in adult patients undergoing minimally invasive cholecystectomy. Participants will be randomly assigned to either the Treatement group (opiranserin + acetaminophen) or the control group (NSAIDs + acetaminophen) in a 1:1 ratio to compare the analgesic efficacy and safety between the two analgesic regimens.

This description comes directly from the study's public registry record.

Talk to the study team

Young Song  ·  02-2019-6692  ·  NEARMYHEART@yuhs.ac

Always discuss trial participation with your own doctor first.

Locations (2)

Gangnam Severance HospitalSeoul, South KoreaNot Yet Recruiting
Gangnam Severance HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07620665